Events After the End of the Reporting Period
Acquisition of Cydectin™
On January 3, 2017, Bayer acquired the Cydectin™ portfolio in the United States from Boehringer Ingelheim Vetmedica Inc., St. Joseph, United States. A payment of €158 million was made on January 3, 2017, in connection with the acquisition.
Leverkusen, February 14, 2017
The Board of Management